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Since the advent of antibiotics more than 50 years
ago, physicians worldwide have relied on their use
for rapid and effective management of infectious
diseases. Formost of this time, antimicrobial agents
were viewedaswonder drugswhichhadprofound
effects on morbidity and mortality from diseases
like pneumonia, and little thought was given to the
consequences of their widespread use. In recent
years, however, the emergence of antimicrobial
resistance has meant that indiscriminate prescri-
bing of these agents is no longer viewed as benign.
Although antibiotics remain the ﬁrst-line therapy
for bacterial infections, it has become evident that
every time an antibiotic is used, it contributes to the
evolution of resistant micro-organisms. Indeed,
over the last fewdecades the incidenceof resistance
has increased in parallel with the number of
antibiotic prescriptions. It has now become appar-
ent that if the emergence and spread of antibiotic
resistant bacterial strains is to be contained, then
physicians must limit the use of antibiotics to
circumstanceswhere they are known to be effective
and their application is clearly necessary. The
desire to control this situation has led many
developed countries to introduce measures to
restrict antibiotic prescribing by clinicians. Never-
theless, these measures have been introduced
largelywithout any understanding of their clinical,
political or ethical impact.
This supplement has been developed against
this setting to provide different perspectives on
the economics of antimicrobial drug development
and supply, and represents the proceedings of an
expert panel meeting that was held at the 15th
European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) in Copenhagen on
5th April, 2005. Speakers at the meeting provided
insights on the impact of antibiotic restrictions
from the point of view of the physician, patient,
payor and pharmaceutical industry, as well as
from an ethical standpoint, and included Dr D.
Price, CPAIG Professor of Primary Care Respir-
atory Medicine at the University of Aberdeen,
UK; Miss B. Wagstaff, MA, an independent
consultant on healthcare policy in the UK; Pro-
fessor H. Goossens, Head of the Department of
Microbiology at the University of Antwerp, Bel-
gium; Dr J. Garau, Head of the Department of
Medicine, Hospital Mutua de Terrassa, Barcelona,
Spain; and Dr E. Power, now Global Medical
Director of the Anti-infectives division at Scher-
ing–Plough Corporation, Kenilworth, USA.
In the ﬁrst article in this supplement, Dr David
Price reviews the policy of restricting antibiotic
prescribing in light of the paucity of data on its
potential implications for patient outcomes or
supporting its efﬁcacy in controlling antibiotic
resistance. Dr Price points out that these issues are
difﬁcult to resolve with randomised clinical trials,
due to the cost of and number of patients required
for such an approach. He suggests epidemiology-
based methods as a means of investigating the
impact of restricting antibiotic use. As an example
of the utility of this approach, he provides
observational data from the UK showing a clear
association between the recent decline in antibi-
otic prescriptions for lower respiratory tract
infections and an increase in mortality from
pneumonia. These data highlight a need for
similar investigations in other countries to exam-
ine fully the impact of restricting antibiotic use on
patient outcomes. Dr Price concludes that, to
optimise patient outcomes, antibiotic policies
must take into account both overprescribing and
underprescribing of antimicrobials.
In the second article, Miss Bronwen Wagstaff
discusses the effect of antibiotic restrictions from
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the patient’s perspective. She suggests that when
patients ask for medical help, they expect health-
care providers and pharmaceutical companies to
protect them, and they rely on such professionals
to provide more beneﬁt to their wellbeing than
harm. Such harm can result both from action on
the part of the healthcare system and inaction; if a
physician advises the patient that no treatment is
necessary then the potential impact of this strat-
egy should be explained fully. Indeed, failure to
do so could well be considered negligence. How-
ever, the physician must balance the need for the
‘best’ therapy from both the patient’s and payor’s
perspectives. Miss Wagstaff concludes that, in the
case of antibiotic prescribing, this balance must
take into account patients’ desire for fast, effect-
ive, and possibly more expensive, therapies with
long-term preservation of antimicrobial efﬁcacy in
the setting of increasing resistance.
Dr Javier Garau provides an overview of the
ethical issues underlying antibiotic restrictions.
He stresses that such restrictions present difﬁcult
choices for physicians, patients and payors, and
points out that the risks of treating patients with
antibiotics or not are not clear-cut; suboptimal
therapy may fail to eradicate the infection, expos-
ing patients to a poorer outcome, whereas failure
to treat patients whose risk of a poor outcome
exceeds the risk of an adverse event is ethically
unacceptable. He suggests that physicians should
identify patients who need antibiotics and then
optimise therapy to achieve the fastest bacterial
and clinical cure; above all, however, they should
treat on the basis of knowledge.
Dr Edward Power reviews the impact of lim-
iting antibiotic use from the pharmaceutical per-
spective. He states that, while pharmaceutical
companies’ investment in antibiotics was high
during the 1970s, research in this area was
severely reduced in the 1980s due to erosion of
commercial interests by ever more widespread
market restrictions. Consequently, he warns that
unless market conditions improve, the develop-
ment of new antibiotic agents is in danger.
Nevertheless, many novel antimicrobial agents
must be developed if we are to counteract the
range of possible outcomes in antibiotic resistance
development. He concludes that innovation and
investment in antibiotic development must be
proactively encouraged to ensure that the next
generation of antibiotics is able to meet this
challenge.
In the foreseeable future, antibiotics are likely
to remain important for the treatment of bacterial
infections both in the hospital and in the commu-
nity settings. This means that it is incumbent on
healthcare professionals, healthcare providers
and industry to maintain a dialogue and to study
new treatment and management options. It is
essential that we work together now to create an
environment in which patients, physicians, pay-
ors and pharmaceutical companies can collabor-
ate effectively to ensure the ongoing availability
of effective antibiotics.
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